A randomized, investigator-blinded study to compare the efficacy and tolerance of a 650-microsecond, 1064-nm YAG laser to a 308-nm excimer laser for the treatment of mild-to-moderate psoriasis vulgaris

Mark S Nestor ,Anita Gade,Haowei Han,Austin Dunn,Francesca Ceci,Alec Lawson,David H Arnold ,Daniel L Fischer

doi:10.25251/skin.5.supp.40

Abstract

N/A

Highlights

The 650-microsecond 1064-nm Nd: YAG laser was introduced in 2009 by Khatri and colleagues and is FDA approved for the treatment of psoriasis
The advantage of the 650-microsecond laser is that treatment does not require cooling or anesthesia because the pulse duration is shorter than or equal to the thermal relaxation time of the therapeutic target
The primary objective of this study was to compare the ability of the 650microsecond, 1064-nm pulsed YAG laser (LightPod Neo®, Aerolase Corp., Tarrytown, NY) to clear psoriatic plaques with that of the 308-nm excimer laser (XTRAC Velocity 400®, PhotoMedex, Inc., Montgomeryville, PA)

Summary

Discussion

Phototherapy is a safe and effective treatment option for psoriasis and does not incur the side effects of systemic medications.[1] The 308-nm excimer laser is considered firstline phototherapy for plaque psoriasis.[1] The excimer laser is able to treat psoriatic lesions with high doses of monochromatic radiation while sparing unaffected skin.[1] The 650-microsecond 1064-nm Nd: YAG laser was introduced in 2009 by Khatri and colleagues and is FDA approved for the treatment of psoriasis. The advantage of the 650-microsecond laser is that treatment does not require cooling or anesthesia because the pulse duration is shorter than or equal to the thermal relaxation time of the therapeutic target. This feature minimizes scarring, pigmentary changes, thermal damage to surrounding tissues, and discomfort during or after treatment.[2]

Objective

Findings

Methods

Conclusion